Abstracts tagged "Patient reported outcomes"

Abstract Number: 2198 • ACR Convergence 2024
Severe and Long-Term Outcomes of COVID-19 Infection and Vaccine Hesitancy and Adverse Events in Children with Pediatric Rheumatic Diseases: Insights from a COVID-19 Global Rheumatology Alliance Caregiver Survey
Jonathan Hausmann¹, Kevin Kennedy², Ethan Knapp³, Nadine Lalonde⁴, jOhn Wallace⁵, Richard Howard⁶, Marcela Alvarez⁷, Mariana Fabi⁸, Lorena Franco⁹, Rebecca Grainger¹⁰, Jean Liew¹¹, Pedro M Machado¹², Zachary Wallace¹³, Jinoos Yazdany¹⁴ and Emily Sirotich¹⁵, and COVID-19 Global Rheumatology Alliance, ¹Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ²McMaster University, Hamilton, ON, Canada, ³University of Connecticut School of Medicine, Farmington, CT, ⁴COVID-19 Global Rheumatology Alliance, London, ON, Canada, ⁵Covid 19 Global Rheumatology Alliance Patient Board, EDINBURGH, United Kingdom, ⁶Spondylitis Association of America, Encino, CA, ⁷CHIDRENS HOSPITAL DR. RICARDO GUTIERREZ ARGENTINA, Buenos Aires, Argentina, ⁸Argentine Society of Rheumatology, La Plata, Argentina, ⁹Argentine Society of Rheumatology, Cordoba, Argentina, ¹⁰University of Otago, Wellington, New Zealand, ¹¹Boston University, Boston, MA, ¹²Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ¹³Massachusetts General Hospital, Newton, MA, ¹⁴UCSF, San Francisco, CA, ¹⁵Yale University, Vaughan, ON, Canada
Background/Purpose: Children have the lowest COVID-19 vaccination rates of any age group. In adults with rheumatic diseases, barriers to vaccination include the perceived lack of…
Abstract Number: PP01 • ACR Convergence 2024
An OCEAN of Change: The Impact of an RA Diagnosis on My Big Five Personality Traits
Laura Sambursky¹ and Lauren Sambursky², ¹Patient, Sarasota, FL, ²Northeastern University, Boston, MA
Background/Purpose: Until age 32, I was a healthy, confident, extraverted, and creative person. I moved hundreds of miles away for college and then earned a…
Abstract Number: 0456 • ACR Convergence 2024
Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis
Jeffrey Curtis¹, Yujie Su², Cassie Clinton³, David Curtis⁴, Laura Stradford⁵, Patrick Zueger⁶, William Benjamin Nowell⁷, Pankaj Patel⁸, Esteban Rivera⁹, Kelly Gavigan⁴, Shilpa Venkatachalam¹⁰ and Fenglong Xie³, ¹FASTER Medicine, Hoover, AL, ²Illumination Health, Hoover, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶AbbVie Inc, North Chicago, IL, ⁷Regeneron, New York, NY, ⁸AbbVie Inc., North Chicago, IL, ⁹Global Healthy Living Foundation, Long Island City, NY, ¹⁰Global Healthy Living Foundation, New York, NY
Background/Purpose: Digital health technology to collect electronic patient reported outcomes (ePRO) and biosensor data are increasingly used to generate real-world data in pharmacoepidemiology. However, the…
Abstract Number: 0679 • ACR Convergence 2024
Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study
Rachel Wallwork¹, Haomin Hu², Ami Shah³, Laura Hummers⁴, John Pauling⁵, Victoria Flower⁶, Bambang Parmanto², Andi Saptono² and Robyn Domsic⁷, ¹Johns Hopkins University, Towson, MD, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵North Bristol NHS Trust, Bristol, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) is the most common symptom in systemic sclerosis (SSc) and can lead to significant morbidity, including digital ulcers and/or gangrene. Despite…
Abstract Number: 1194 • ACR Convergence 2024
Treatment Effect of Lorecivivint Across Multiple Trials in Patients with Knee OA: A Meta-analysis
Christopher Swearingen¹, Jeyanesh Tambiah² and Yusuf Yazici³, ¹Biosplice Therapeutics, Inc, San Diego, CA, ²Biosplice Therapeutics Inc., San Diego, CA, ³NYU Grossman School of Medicine, La Jolla, CA
Background/Purpose: Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways has previously appeared safe, improved patient-reported outcomes (PROs) compared with…
Abstract Number: 1285 • ACR Convergence 2024
The Impact of Race and Social Determinants of Health on Patient Reported Outcomes in Pediatric Lupus: A CARRA Registry Study
William Soulsby¹, Rebecca Olveda², Jie He³, Laura Berbert⁴, Edie Weller³, Kamil Barbour⁵, Kurt Greenlund⁵, Laura Schanberg⁶, Emily Von Scheven¹, Aimee Hersh⁷, Mary Beth Son⁸, Joyce Chang⁸ and Andrea Knight⁹, and the CARRA Registry Investigators, ¹University of California, San Francisco, San Francisco, CA, ²Palo Alto Medical Foundation, Dublin, CA, ³Boston Children's Hospital, Boston, MA, ⁴Boston Children's Hospital, Belmont, MA, ⁵CDC, Alpharetta, GA, ⁶Duke University Medical Center, DURHAM, NC, ⁷University of Utah, Salt Lake City, UT, ⁸Boston Children's Hospital, Brookline, MA, ⁹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Minoritized race and social determinants of health (SDoH) are associated with lower achievement of the low lupus disease activity state (LLDAS) and higher cumulative…
Abstract Number: 1480 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Victoria Navarro Compán¹, Maureen Dubreuil², Karl Gaffney³, Jonathan Kay⁴, Christine de la Loge⁵, Ute Massow⁶, Vanessa Taieb⁷, Thomas Vaux⁸ and Atul Deodhar⁹, ¹La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ²Section of Rheumatology, Boston University School of Medicine, Boston, MA, ³Health Care - NHS, Norwich, United Kingdom, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Slough, United Kingdom, ⁹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In the phase 3 BE MOBILE 1 and 2 studies, bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits interleukin (IL)-17F in addition to IL-17A,…
Abstract Number: 2093 • ACR Convergence 2024
Treatment of Advanced Knee OA with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial
Christopher Swearingen¹, Yusuf Yazici², Jeyanesh Tambiah³ and Philip G Conaghan⁴, ¹Biosplice Therapeutics, Inc, San Diego, CA, ²NYU Grossman School of Medicine, La Jolla, CA, ³Biosplice Therapeutics Inc., San Diego, CA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways, demonstrated beneficial effects on clinical and radiographic outcomes in previous knee…
Abstract Number: 2209 • ACR Convergence 2024
Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis
Michael George¹, Kelly Gavigan², Shilpa Venkatachalam³, David Curtis², Laura Stradford⁴, William Benjamin Nowell⁵, Joshua Baker¹, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Regeneron, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Serious infections are a major cause of morbidity and mortality in patients with RA, but less is known about more common, non-serious infections. We…
Abstract Number: PP03 • ACR Convergence 2024
How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities
Shelley Fritz, Global Healthy Living Foundation, Kalaheo, HI
Background/Purpose: Twelve years ago, I was diagnosed with rheumatoid arthritis (RA). Initially, I was hopeful that the first biologic DMARD would slow the disease and…
Abstract Number: 0534 • ACR Convergence 2024
Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis
Alexandre Matar¹, Maya Breitman², Tracey Bonfield³, Maricela Haghiac⁴, Jane Reese³, Emma Barnboym⁵, Steven Lewis⁶, Hillard Lazarus⁷ and Nora Singer⁸, ¹MetroHealth, Westlake, OH, ²MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Metrohealth Medical Center, Cleveland, OH, ⁵The MetroHealth System, Cleveland, OH, ⁶Case Western University, MetroHealth, Cleveland, OH, ⁷Case Western Reserve University/University Hospitals, Cleveland, OH, ⁸MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Mesenchymal stem (stromal) cells (MSCs) constitute an emerging therapeutic strategy for several human diseases. Small non-randomized studies have shown that MSCs may be a…
Abstract Number: 0680 • ACR Convergence 2024
Clinical Correlates of Physical and Mental Health in Early Systemic Sclerosis: Data from the Collaborative National Quality and Efficacy (CONQUER) Registry
Ashima Makol¹, Isha Lamba², Dinesh Khanna³, John VanBuren⁴, Angela Child⁴, Jessica Alvey⁴, Shervin Assassi⁵, Elana Bernstein⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Faye Hant¹¹, Laura Hummers¹², Kimberly Lakin¹³, Dorota Lebiedz-Odrobina¹⁴, Yiming Luo¹⁵, Jerry Molitor¹⁶, Duncan Moore¹⁷, Carrie Richardson¹⁸, Nora Sandorfi¹⁹, Ami Shah²⁰, Ankoor Shah²¹, Brian Skaug⁵, Virginia Steen²², Elizabeth Volkmann²³ and Jessica Gordon²⁴, ¹Mayo Clinic, Rochester, MN, Rochester, MN, ²New York Presbyterian Hospital/Weill Cornell Medical Centre, New York, NY, ³University of Michigan, Ann Arbor, MI, ⁴University of Utah, Salt Lake City, UT, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ⁷Massachusetts General Hospital, Boston, MA, ⁸Stanford University, Woodside, CA, ⁹Scleroderma Research Foundation, Brisbane, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ¹³Hospital for Special Surgery, New York, NY, ¹⁴University of Utah, Cottonwood Heights, UT, ¹⁵Columbia University, New York, NY, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Northwestern Memorial Hospital, Chicago, IL, ¹⁸Northwestern University, Chicago, IL, ¹⁹University of Pennsylvania, Philadelphia, PA, ²⁰Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ²¹Duke University, Durham, NC, ²²Georgetown University School of Medicine, Washington, DC, ²³University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles, ²⁴Division of Rheumatology, Weill Cornell Medical College, New York, NY
Background/Purpose: Early years of Systemic sclerosis (SSc) are typically the period of peak disease activity and associated with greater pain, fatigue, sleep disturbance, physical impairment,…
Abstract Number: 1229 • ACR Convergence 2024
Frequency of Fibromyalgia Using Validated Measures in a Sample of Patients with Psoriatic Arthritis and Impact on Disease: A Cross-Sectional Multinational Study
avin maroof¹, Nelly Ziade², Lina El Kibbi³, Bassel Elzorkany⁴, Nizar Ani⁵, ASAL ADNAN RIDHA⁶, Faiq Gorial⁷, NABAA IHSAN JAWAD AWADH⁸, Nada Al Chama⁹, Chafika Haouichat¹⁰, Fatima Alnaimat¹¹, Suad Mohamed Abdulla Hannawi¹², Suad Hannawi¹³, Saed Atawnah¹⁴, HUSSEIN HALABI¹⁵, Manal Al-Mashaleh¹⁶, Ahmed Abogamal¹⁷, Rachid Bahiri¹⁸, Sahar Saad¹⁹, maha sabkar²⁰, Krystel Aouad²¹, Laure Gossec²², Ihsane Hmamouchi²³, nabaa abbas²⁴, Elyes Bouajina²⁵, Laila Aljazye²⁶ and Laila ayoub²⁷, and ArLAR-ARCH group, ¹University of Kurdistan Hawler, Erbil, Iraq, ²Saint-Joseph University, Beirut, Lebanon, ³Division of rheumatology / Department of Medicine / Specialized Medical Center, Riyadh, Saudi Arabia, ⁴Private (BZRC), Cairo, Egypt, ⁵Baghdad College of Medicine, Baghdad, Iraq, ⁶Baghdad Teaching Hospital, baghdad, Iraq, ⁷Rheumatology Unit/Department of Medicine/ College of Medicine/ University of Baghdad, Baghdad, Iraq, ⁸Baghdad Teaching Hospital / Medical City, Baghdad, Iraq, ⁹Rheumatology Department / Ebn Al Nafiss Hospital / Damascus, Damascus, Syria, ¹⁰Djillali Bounaama university hospital, Algiers, Algeria, ¹¹The University of Jordan, amman, Jordan, ¹²Rheymatology Department / Emirate Health Services / Dubai, Dubai, United Arab Emirates, ¹³Ministry of Health and Prevention, Dubai, United Arab Emirates, ¹⁴Al-Quds University / Alahli Hospital / Hebron ,Palestine, Hebron, Palestinian Territories, ¹⁵King Faisal Specialist Hospital / Jeddah, Jeddah, Saudi Arabia, ¹⁶Royal Medical Services, Amman, Jordan, ¹⁷Dr. Sliman Al Habib Hospital / Al-Azhar Faculty of Medicine, Dubai, United Arab Emirates, ¹⁸El Ayachi Hospital / Medical University Hospital / Rabat, Rabat, Morocco, ¹⁹King Hamad University Hospital / Assiut Medical School of Egypt, Al Sayh, Bahrain, ²⁰King Hamad university Hospital, Arad, Bahrain, ²¹Saint George Hospital University Medical Center, Beirut, Lebanon, ²²Sorbonne Université, Paris, France, ²³Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco, ²⁴Baghdad teaching hospital, Medical city, Baghdad, Iraq, Baghdad, Iraq, ²⁵Farhat Hached Hospital of Sousse, Tunisia, Sousse, Tunisia, ²⁶Tripoli / Libya, Tripoli, Libya, ²⁷Rheumatology unit, department of internal medicine, Tripoli Central Hospital. Faculty of Medicine, University of Tripoli, Libya, Tripoli, Libya
Background/Purpose: Fibromyalgia (FM), a chronic pain disorder, is more prevalent in psoriatic arthritis (PsA) patients, impacting quality of life and potentially leading to unnecessary treatment escalation. Cultural factors may…
Abstract Number: 1320 • ACR Convergence 2024
Acceptability and Satisfaction of an Online Resilience-Building Intervention with Peer Health Coaches for Managing Fatigue and Well-Being in Systemic Sclerosis
Susan Murphy¹, Yen Chen², Alexandra Harper², Nirali Shah², Mary Alore², Sheri Hicks², Adam Pape³ and Dinesh Khanna², ¹University of Michigan, Plymouth, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, University of Michigan, MI
Background/Purpose: Non-pharmacological fatigue management interventions in systemic sclerosis (SSc) are limited, despite people with SSc reporting that fatigue is inadequately addressed with clinical care. We…
Abstract Number: 1500 • ACR Convergence 2024
Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres
Behdin Nowrouzi-Kia¹, J. Antonio Avina-Zubieta², Mary Fox³, William Shaw⁴, Maggie Ho⁵, Qixuan Li⁵, Catherine Ivory⁶, Paul Fortin⁷, Stephanie Keeling⁸, Jennifer Reynolds⁹, Derek Haaland¹⁰, Janet Pope¹¹, Lily Lim¹², Patti Katz¹³, Murray Urowitz¹⁴, Laura Patricia Whittall Garcia⁵, Dafna Gladman¹⁵ and Zahi Touma¹, ¹University of Toronto, Toronto, ON, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³York University, Toronto, ON, Canada, ⁴University of Connecticut, School of Medicine, Farmington, CT, ⁵University Health Network, Toronto, ON, Canada, ⁶The Ottawa Hospital, Ottawa, ON, Canada, ⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹UBC, North Vancouver, BC, Canada, ¹⁰The Waterside Clinic, Oro Medonte, ON, Canada, ¹¹University of Western Ontario, London, ON, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada, ¹³UCSF, San Rafael, CA, ¹⁴Self employed, Toronto, ON, Canada, ¹⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) has a significant and long-lasting impact on work outcomes, is a source of long-lasting work disability, and presents challenges with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].